Systemic Inflammatory Response to CCRE

Exclusion Criteria

• •1. Any chronic medical condition considered by the PI as a contraindication to the exposure study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, or chronic thyroid disease.
• •2. Physician directed emergency treatment for asthma exacerbation within the preceding 3 months.
• •3. Moderate or Severe asthma
• •4. Exacerbation of asthma more than 2x/week that would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
• •5. Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma
• •6. Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
• •7. History of intubation for asthma
• •8. Daily use of NSAIDs, or inability to withhold NSAIDs for 4 days prior to dosing.
• •9. Use of medications that may impact the results of the study to include, but not limited to, systemic corticosteroids, beta blockers.
• •10. Cigarette smoking \> 1 pack per month.
• •11. BMI\>35.
• •12. Pregnant or breast feeding women will not be included.
• •13. Subjects who are employed within the past 6 months in an occupation with high risk for endotoxin exposure, such as grain storage sites or swine containment.
• •14. Subjects will be deferred after any acute, non-chronic medical condition requiring treatment, such as bronchitis, pneumonia or febrile illness for a minimum of 4 weeks after complete resolution of symptoms.
• •\-